Leukemia and lymphoma

Leukemia and lymphoma alternative treatment:

The primary condition created with a misaligned jaw is that the pain neurotransmitter levels

hematopoesis leukemia and lymphoma alternative treatment

hematopoesis

become elevated (substance P).  Research has shown that substance P modulates the entire leukemia an lymphoma phenomenon through modulation of haematopoiesis (formation of all of components of blood). See Substance P and Hematopoesis article.

Leukemia and lymphoma alternative treatment through dental orthopedic appliances repositions the lower jaw to an ideal position.  This calms the trigeminal nerve and thus lowers systemic substance P levels. Lowered substance P levels allows the stem cells to correct their output.

To date, having evaluated a very limited number of cases, dental orthopedic therapy has  seemed to be very effective at reversing leukemia and lymphoma symptoms.

References:

Leukemia. 2003 Jun;17(6):1096-9.

Substance P–a potent risk factor in childhood lymphoblastic leukaemia.

Source

Department of Paediatric Haematology and Oncology, Institute of Paediatrics, Poznan, Poland.

Abstract

The study focused on determining the expression of substance P (SP) in neoplastic bone marrow cells in childhood acute lymphoblastic leukaemia (ALL) in terms of its mRNA and the level of protein production. An attempt has also been made to demonstrate a correlation of SP with leukaemia risk factors and treatment failure. The study group comprised 120 children treated for ALL. Expression of SP was examined by in situ hybridisation with a 5′-biotinylated probe and by immunocytochemistry with specific anti-human SP antibody. Out of 80 patients with common ALL, the expression of SP was demonstrated in 33 cases (41.2%). In the group of 24 children with pre-B ALL, the presence of SP was noted in six cases (25.0%). Of 16 patients with T-cell leukaemia, SP expression was demonstrated in 13 cases (81.2%). The percentage of immunopositive cells in the SP-positive cases ranged from 79.8 to 97.3. Treatment failure in the children with ALL was closely related to the expression of SP observed at the beginning of treatment. The results showed a connection between the presence of SP-positive blasts and leukaemia relapse. This may indicate that SP expression, involved in the proliferation of the tumour cells, may represent a novel risk factor in ALL.

PMID: 12764374

J Clin Pathol. 2006 Sep;59(9):935-41.

The predicting role of substance P in the neoplastic transformation of the hypoplastic bone marrow.

Source

Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznan, Poland. mnowicki@amp.edu.pl

Abstract

AIMS:

To estimate the expression of substance P in the haematopoietic cells of hypoplastic bone marrow and define its relationship with the course of bone marrow hypoplasia.

METHODS:

Bone marrow specimens were obtained from 42 children with bone marrow hypoplasia who were hospitalised in the Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznan, Poland, between 1996 and 2003. Substance P and Ki-67 expression were evaluated using immunochemical and hybridocytochemical assays.

RESULTS:

The expression of substance P (as evidenced by both immunocytochemical and hybridisation techniques) was confirmed in the cytoplasm of B lymphocytes in 8 of 11 children who developed acute leukaemia in 45 (SD 12) days. The percentage of substance P-positive cells ranged from 67.6 to 95.8 (mean of 81.5% cells with immunocytochemistry and 84.3% with in situ hybridisation). The risk of development of leukaemia secondary to bone marrow hypoplasia was found to be significant (p<0.001) in those children who expressed substance P in normal-looking lymphocytes at the initial bone marrow evaluation.

CONCLUSIONS:

The presence of substance P in B lymphocytes of hypoplastic bone marrow may predict its neoplastic transformation. A marked correlation between substance P-positive bone marrow pattern and the expansion of tumour cells may prove the potential value of this oligopeptide in the pathogenesis of leukaemia.

PMID: 16935970

Leave a Reply

Your email address will not be published. Required fields are marked *